protease-releasable masking technology in infectious diseases and cancer, respectively.

We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola.

Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients.